Topics

Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic

06:00 EDT 30 Apr 2019 | Xconomy

Vividion Therapeutics, a biotechnology company that launched in 2017 around discoveries made in Scripps Research Institute labs, has raised $82 million in financing. Nextech Invest, a Swiss investment firm that funds companies developing cancer therapeutics, led the Series B round of funding. As part of the investment, Nextech partner Jakob Loven gets a board seat. […]

Original Article: Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic

NEXT ARTICLE

More From BioPortfolio on "Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic"

Quick Search

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...